Preparative regimens without total body irradiation (TBI) have been reported for alternative donor hemopoietic stem cell transplants (HSCT). Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and antithymocyte globulin (ATG). Donors were HLA mismatched family members (1-2 antigens) (FAM) (n = 24, median age 31 years) or HLA matched unrelated donors (UD) (n = 24, median age 34 years). GVHD prophylaxis was cyclosporine and methotrexate. Stem cell source was peripheral blood (n = 8) or bone marrow (n = 40). Hematologic recovery was seen in 42/46 (91%) evaluable patients and complete chimerism in 31/37 patients (85%). Acute GVHD grades III-IV were seen in 10/46 patients surviving 10 days (21%) and extensive chronic GVHD in 2/36 patients surviving 100 days (5%). Twenty-six patients died (54%), eight of recurrent disease (17%) and 18 of transplant-related complications (37%): main causes of TRM were GVHD (15%), infections (15%) and graft failure (4%). Alternative donors are being increasingly used for hemopoietic stem cell transplants (HSCT) since many patients eligible for this procedure lack an HLA-identical sibling. Alternative donors can be found within the patient's family, with various degrees of HLA mismatch, or among the international network of unrelated donors. The number of family mismatched (FAM) grafts has been stable over the past years in Europe, and represents approximately 4% of allogeneic HSCT.
Alternative donors are being increasingly used for hemopoietic stem cell transplants (HSCT) since many patients eligible for this procedure lack an HLA-identical sibling. Alternative donors can be found within the patient's family, with various degrees of HLA mismatch, or among the international network of unrelated donors. The number of family mismatched (FAM) grafts has been stable over the past years in Europe, and represents approximately 4% of allogeneic HSCT. 1 On the other hand, the number of unrelated donor grafts (UD) has been increasing by approximately 25% per year and currently represents 30% of allogeneic HSCT. 1 Conditioning regimens for alternative donor HSCT in patients with hematologic malignancies typically include cyclophosphamide (CY) and total body irradiation (TBI), although busulfan-based conditioning regimens have also been reported. Anderson and coworkers 2 found no significant difference when comparing busulfan-cyclophosphamide (BU-CY) to CY-TBI for patients with refractory anemia grafted from family or unrelated donors. Similar encouraging results have been reported with the use of busulfan by other investigators. [3] [4] [5] [6] [7] The choice of conditioning depends on whether the graft is manipulated or not: T cell depletion requires an intensive immunosuppressive conditioning regimen, because of the increased risk of graft failure, 8 whereas unmanipulated grafts may be given after less intensive preparation because of the promoting effect of T cells on engraftment.
One agent that has been tested in several conditioning regimens over the past years is thiotepa: it was originally used with cyclophosphamide (CY) for autologous transplants 9 and more recently with single-dose TBI, CY and ATG for mismatched HSCT. 10 It possesses potent myeloablative and immunosuppressive activity. 11 We have previously described a conditioning regimen consisting of thiotepa (THIO) and CY for HLA-identical sibling HSCT in patients with hematologic malignancies. 12 We have now grafted 94 patients from HLA-identical siblings with the THIO-CY protocol, and have raised the upper age limit to 60 years. 13 The median age of these 94 patients is 48 years (21-60) and transplant-related mortality (TRM) 20%, either in younger or older patients (21-48 or 49-60). The actuarial 3-year survival is 51% (73% for 39 patients in first remission and 38% for 55 patients with more advanced disease) (unpublished). The proportion of patients achieving full donor chimerism by day +100 is between 80% and 100%, depending on the dose of THIO-CY and on the source of stem cells (bone marrow or peripheral blood), and persistent take has been documented up to our longest follow-up which is now 5 years post graft.
14 Therefore, the THIO-CY combination has proven effective in allowing engraftment in the HLA-identical sibling transplant setting, with relatively low toxicity and acceptable efficacy on the underlying disease.
In an attempt to increase the immunosuppressive potency of the regimen, we added antithymocyte globulin (ATG) to the THIO-CY conditioning 4 years ago, and tested this combination as conditioning for HSCT from alternative family mismatched or unrelated donors: major end points of the study were engraftment and GVHD. We now report 48 consecutive patients grafted with the THIO-CY-ATG protocol.
Materials and methods

Patients
Patients eligible for this trial had advanced disease (not in first remission/chronic phase), an unrelated donor and no available TBI session, or a partially mismatched family donor. Forty-eight consecutive patients entered this study and received an unmanipulated allogeneic HSCT at our unit between 7 September 1994 and 7 June 1999. Clinical details are outlined in Table 1 . Patients were cared for in single rooms with HEPA-filtered air from day −7 until at least day +30, when they were discharged either to a conventional care unit, or to the outpatient clinic. All patients received high-dose immunoglobulins (HDIgG) 400 mg/kg/ week from day −7 until day +100. In the event of major ABO incompatibility the marrow was not depleted of red cells, but isohemagglutinins were reduced in the patient to a titre of р1:16 in saline, with one or two plasma exchanges performed on days −2 and −1 before HSCT.
HLA matching: Of the family mismatched transplants (FAM) four were mismatched for one antigen either in the GVHD direction (n = 3) or in the host-versus-graft (HVG) direction (n = 1); 13 patients were mismatched for one antigen in both the GVHD and the HVG direction and seven patients were mismatched for two antigens in the HVG direction and one antigen in the GVHD direction. Twelve patients were mismatched at class I, five at class II and seven at class I + class II. The donor was a parent in 11 cases, a son in four and a sibling in nine.
Twenty-four patients had matched unrelated donor (UD) selected by the Italian Bone Marrow Donor Registry (IBMDR): donors were matched by serology for class I antigens, including split antigens, and by molecular biology for class II, including high resolution sequence-based typing (SBT) for DRB1.
Conditioning regimen
The conditioning consisted of thiotepa 5 mg/kg on day −7 and 5 mg/kg × 2 on day −6 (total dose 15 mg/kg), rabbit Unrelated donor bone marrow transplants: Bone marrow was harvested from unrelated donors in the respective harvest centers and transferred via courier to our unit without further manipulation.
Family mismatched donors:
All 24 HLA mismatched family donors donated G-CSF-mobilized hemopoietic stem cells. The first eight donated peripheral blood cells (PBC) (one or two aphereses) after mobilization with G-CSF 10 g/kg/day for 4 consecutive days. The following 16 donated bone marrow (BM) after 1-day mobilization with G-CSF 10 g/kg. In detail, PBC donors received G-CSF 10 g/kg/day on days −4, −3, −2, −1 and underwent leukapheresis on day 0 (+1). BM donors received G-CSF 10 g/kg/day on day −1 and 5 g/kg on day 0: on the same day they underwent general anesthesia and a bone marrow harvest. Bone marrow was harvested as reported, using small volume aspirations, and the total harvested volume was 20-25 ml/kg of donor body weight; it was processed through small gauge needles (20G) to avoid loosing cells in the infusion filters. The median numbers of cells infused are outlined in Table 1 .
GVHD prophylaxis
All patients received CyA 1 mg/kg as a continuous i.v. infusion from day −7 to day −2, then 2 mg/kg i.v. from day −1 to day +20, and then 5-10 mg/kg/day p.o. from day +21 until at least day +365. Methotrexate (MTX) was given at the conventional dose of 15 mg/m 2 on day +1, and 10 mg/m 2 days +3 , +6 and +11.
CMV prophylaxis
All patients received foscarnet from day −7 to day +30 at a dose of 30 mg/kg twice daily, then 90 mg/kg/day 5 days/week from day +31 to day +100.
CMV treatment
Patients were monitored once a week from day +1 to day +30 then twice weekly until day +100 for CMV antigenemia, as described elsewhere. 15 CMV antigenemia was treated by adding ganciclovir (5-10 mg/kg/day for 15 days) to the prophylactic foscarnet. 16 Engraftment and chimerism: Thirty-seven patients were monitored for donor/recipient chimerism by cytogenetic analysis, erythrocyte typing, and microsatellite analysis: 11 patients were either not studied for chimerism (n = 7) or died too early (n = 4).
Donor lymphocyte infusions (DLI):
These were given in escalating doses, in cases of relapse as described 17 for patients receiving an unrelated donor graft (1 × 10 6 /kg followed 21 days later by 1 × 10 7 /kg). For FAM mismatched donors the dose of lymphocytes was reduced by one log: 1 × 10 5 CD3 + cells/kg followed by 1 × 10 6 CD3 + cells/kg 3 weeks later in the absence of GVHD.
Control CML group: Twenty-one CML patients in accelerated phase, prepared with CY 120 mg/kg and total body irradiation (TBI) (9.9 Gy in three doses or 12 Gy in six doses) and grafted concurrently from unrelated donors in our unit, were used as controls. All these patients had a TBI session available at the time of transplant: clinical details are outlined in the Results section.
Statistical analysis
The chi-square test was used for 2 × 2 tables; the rank sum and t-test were used for differences between continuous variables; the Kaplan-Meier actuarial survival plots were used for time-dependent analysis (survival, transplant mortality and relapse). TRM was defined as death due to causes other than relapse.
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Results
Patients
As shown in Table 2 , both groups of FAM and UD patients spent a considerable number of days in hospital, the median being 42 and 55, with highs of 113 and 120 days. This implies that some of these patients were quite sick, with fever, and required prolonged treatment in hospital.
Engraftment
Median days to 0.5 × 10 9 /l neutrophils were 17 in FAM and 18 in UD grafts ( TRM = transplant-related mortality; MOF = multiorgan failure; CMV = cytomegalovirus; dd = days Bone Marrow Transplantation of transplant). Eleven patients were either not studied for chimerism (n = 7) or died too early (n = 4) Thirty-seven patients were studied for chimerism: 31/37 (85%) had 100% donor cells, 2/37 (5%) had 90-95% donor and 2/37 (5%) had 50-60% donor cells and two patients (5%) had 0-3% donor cells.
Graft failure: Two patients died of graft failure. One patient with CML had received interferon treatment for 9 years and had significant fibrosis pre-HSCT (UD graft): he proved intolerant of ATG and did not complete even the first day. There was no take and the patient never achieved a neutrophil count of 0.5 × 10 9 /l: he died on day +108 of infection, after failing to recover after infusion of 3 × 10 8 /kg autologous BM cells harvested 3 years prior to HSCT. The second patient was a CML grafted with BM cells from her 23-year-old two antigen mismatched daughter. She had a bilateral pneumonia due to Staphylococcus aureus early post HSCT, but recovered. The take was good and on day +50 her WBC count was 4 × 10 9 /l and her platelet count was 110 × 10 9 /l. Her WBC counts then dropped rapidly down to 0.1 × 10 9 /l in 10 days and became infected; she was given a combination of cyclophosphamide and fludarabine and a second graft with G-CSF mobilized PB cells (day +90). There was no take and the patient died with pancytopenia on day +105 from the first graft.
Immune reconstitution
CD4 counts were available in 26 patients: CD4 absolute counts/mm 3 at days +20, +50, +100, +180, +365 were respectively 26, 70, 123, 196, 502/cmm. CD4 counts were higher but not significantly so in FAM mismatched transplants when compared to UD transplant recipients.
GVHD
Acute GVHD (aGVHD) occurred at a median interval from HSCT of 15 days (7-32) vs 9 (6-31) in FAM and UD grafts respectively (P = 0.1). aGVHD was scored as grades 0-I, grade II, grades III-IV in six, 14, four patients in FAM and nine, nine, six patients in UD grafts (P = 0.4) ( Table 2) . Chronic GVHD was assessed in patients alive on day +100 and was scored as absent, limited or extensive in 12, seven, one patients in FAM grafts and 11, four, one patients in UD grafts (P = 0.3) ( Table 2 ). Overall, 21% of patients had severe aGVHD and 5% extensive cGVHD.
Hemolytic anemia developed in two patients grafted from a one antigen mismatched FAM donor: both were major ABO mismatched pairs, and both responded to combined immunosuppressive treatment and plasma exchange. We also compared the 16 patients who received no ATG or 2 days of ATG with the 32 patients who received the full dose of ATG: aGVHD grades III-IV were scored in 31% vs 15%, respectively (P = 0.2), which reached statistical significance if only FAM grafts were considered (33% vs 0%, P = 0.03).
CMV infections
Twenty-five patients developed CMV antigenemia and the actuarial risk at 1 year was 68% (63% vs 73% in FAM vs UD grafts, P = NS). There was no difference in the number of CMV antigen-positive cells at diagnosis of the infection in the two groups. Developing CMV antigenemia did not change the likelihood of TRM (P = 0.8). Indeed, no patient died of CMV disease.
Transplant-related mortality
Eighteen patients died of transplant-related complications (TRM) (37%). Major causes of failure were acute GVHD (15%), infections (15%) and graft rejection (4%). The actuarial 3-year transplant-related mortality is 26% and 51% (Figure 1 ) for FAM and UD grafts, respectively (P = 0.09) and the difference was more evident when BM transplants only were studied (18% vs 51%, P = 0.05). There was no significant effect of age (Ͻ/у33 years) or of disease phase, although only six patients were in first remission/chronic phase, nor of diagnosis since the 28 CML patients had the same TRM as the 20 non-CML patients (37% vs 40%). There was an effect of cell dose: the actuarial TRM of patients receiving р3.8 × 10 
HLA mismatch and TRM
Of the family mismatched transplants (FAM) four were mismatched for one antigen either in the GVHD direction (n = 3) or in the HVG direction: their TRM is 8%; 13 patients were mismatched for one antigen in both the GVHD and the HVG direction and their TRM is 27%; seven were mismatched for two antigens in the HVG direction and one antigen in the GVHD direction and had a TRM of 15%.
When mismatch in the GVHD direction was added to mismatch in the HVG direction there were four, 13 and seven patients with 1, 2, 3, antigen mismatch: their TRM was 25%, 30%, 14% (P = 0.6). We also analyzed the effect of class I and class II mismatch: the number of patients who died of TRM was 3/10, 1/3, 1/5, 1/6 respectively for patients mismatched for 1 class I antigen, 2 class I antigens, 1 class II antigen and 1 class I+ 1 class II antigens. For A mismatch TRM was 2/5, for B mismatch 1/5, for A+B mismatch 1/3, for B+DR mismatch 1/5. The numbers are small but we could find no significant difference in the type of mismatch.
Source of stem cells
All UD transplants were performed using bone marrow. Of the FAM transplants 8 were from PB cells and 16 from BM cells : acute GVHD grades III-IV were seen, respectively, in 33% vs 8% of patients (P = 0.04), extensive chronic GVHD in 6% vs 0% (P = NS). TRM was 43% for PB grafts vs 18% for BM grafts (P = 0.7) and the survival 29% vs 58% (p = 0.1).
Relapse and donor lymphocyte infusions (DLI)
The overall actuarial risk of relapse at 3 years was 58%. Its was 0% for the small number of patients (n = 6) in first remission/chronic phase, and 62% for 42 patients with more advanced disease. DLI were given to seven patients (four with CML) at escalating doses. Two CML patients had a complete cytogenetic response, but one died of acute GVHD. Five patients showed no response and no GVHD.
Survival and causes of death
Twenty-two patients (46%) survive with a median followup of 729 days (137-1687). The actuarial 3-year survival is 49% for FAM and 42% for UD transplants (Figure 2) . Twenty-six patients died (54%), eight of recurrent disease (17%) and 18 of transplant-related complications (TRM) (37%). Among the latter were GVHD (15%), infections (15%), graft failure (4%), other (3%). 
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Comparison of the thiotepa-based regimen with a TBIbased regimen
Results obtained in 15 patients with advanced CML grafted from UD with the thiotepa-based regimen, were compared to 21 concurrent patients with advanced CML grafted from UD with a TBI-based regimen: severe aGVHD was 27% in the thiotepa-based regimen vs 33% in the TBI-based regimen (P = 0.6). The actuarial 3-year TRM was, respectively, 44% and 38% (P = 0.3), survival was 53% vs 63% (P = 0.3), and relapse 50% vs 26% (P = 0.2). When patients receiving less than 2 × 10 8 /kg cells were excluded from the analysis, TRM was superimposable (29% vs 27%, P = 0.8). Indeed, cell dose was a predictor of outcome in this group of UD-BMT patients: 59% vs 19% TRM for patients receiving р/Ͼ 3.6 × 10 8 /kg (P = 0.05). Causes of death in the THIO-CY-ATG group compared to the CY-TBI group were as follows: rejection 7% vs 0%, aGVHD 12% vs 9%, infections 13% vs 5% and relapse 7% vs 5%.
Discussion
Conditioning regimens without total body irradiation have the advantage of not requiring a radiotherapy department with a dedicated program, and can therefore also be used easily in smaller institutions. Among several possible drug combinations, the busulfan-cyclophosphamide regimen (BU-CY) first described by Santos and co-workers 18 in the late 1970s, is widely used and has been shown to produce similar survival when compared to cyclophopshamide and total body irradiation (CY-TBI) in HLA-identical sibling transplants. 19 Liver toxicity is one important complication in patients receiving the BU-CY regimen. In a multicenter analysis of 350 patients prepared for transplant with busulfan, the incidence of VOD was 27%, with 11% having severe VOD and a high mortality. 20 Until recently, however, it was unclear whether this risk of VOD was greater for BU-CY-treated patients as compared to those receiving CY-TBI. Three recent studies have analyzed this issue. The first is a meta-analysis of five randomized trials, which included 652 patients, of whom 314 received TBI and 338 BU-CY: 21 a significantly greater incidence of VOD was shown for patients receiving BU-CY with an odds ratio of 2.5 (range 1.2-5.2, P = 0.02). Survival and disease-free survival were superior in the CY-TBI, but not significantly so. The second report is an IBMTR study looking at 1717 patients for factors predictive of liver complications: again, busulfan is identified as a significant predictor of VOD with an odds ratio of 2.8, in keeping with the result of the metaanalysis. 22 Finally, an update of a randomized trial by the Nordic BMT group on 167 patients has recently been published. 23 The study shows a significantly increased risk of early (VOD) as well as late complications such as chronic GVHD and obstructive bronchiolitis, for BU-CY as compared to CY-TBI; survival was superior for TBI patients with advanced disease. 23 Therefore, BU-CY is slightly inferior to the CY-TBI regimen in terms of survival and significantly worse in terms of liver toxicity. A most recent analysis of the IBMTR confirms that this is also true for children with ALL.
These problems with busulfan-based regimens, suspected for some years and confirmed by the long list of publications appearing between 1995 and 2000, were the major reason for seeking an alternative drug. One could, of course, question why a TBI-free regimen should be sought. The answer, in our setting, would be that we had a limited number of TBI sessions per year, and it was difficult at times to co-ordinate the marrow harvest from unrelated donors with the days of radiation. Indeed, unrelated harvests have a greater chance of being delayed for medical or organizational reasons on the donor's side. The choice of thiotepa came about because we had been using the combination THIO-CY successfully for HLA matched sibling HSCT 12, 13 and wanted to test this conditioning regimen in alternative donor grafts too with the addition of ATG. Because this was a pilot study we elected to treat patients with advanced disease, and indeed, 88% of the patients were beyond first remission or first chronic phase.
Hemopoietic recovery was the primary end point of the study and was seen in the majority of the 48 patients prepared with THIO-CY-ATG (91%). One patient never recovered his neutrophils after an unrelated graft and died after 4 months of neutropenia: he also failed to recover after infusion of an adequate number of autologous cryopreserved marrow cells. An additional patient showed full hematologic recovery after a family mismatched graft, but rejected abruptly and died after failing to recover after a second transplant. Therefore, 2/48 patients (4%) died without sustained hematologic recovery. This is higher than we had seen with HLA-identical siblings (0/94) but not significantly so (P = 0.1) The proportion of patients with full donor chimerism was 85%, due to the fact that some patients died early and could not be evaluated and some initially had mixed chimerism: there were, however, two patients with less than 10% donor cells beyond day +100. Engraftment was stable and all survivors in remission are full donor chimeras. Platelet recovery was faster, although not significantly so in patients receiving FAM mismatched grafts, and indeed the number of marrow cells grafted was significantly greater in the latter group.
GVHD was the second end point of this study. GVHD grades II-IV were seen in 68% of the patients, and grades III-IV in 21%: this is not a low incidence of GVHD, but it is comparable to our concurrent series of UD transplants after CY-TBI and perhaps somewhat lower (27% vs 33%). Although the number of patients is small we could not find a 'vector' effect as described by Anasetti and coworkers: 25 severe acute GVHD was seen in pairs with donor or recipient incompatibilities. Overall, the risk of severe acute GVHD was similar in recipients of family mismatched grafts as compared to unrelated donor marrow grafts, but lower if one considers recipients of bone marrow transplants only (6% vs 25%, P = 0.1). Extensive chronic GVHD was recorded in 5% of patients.
Transplant-related mortality was the other important end point: two patients died before day +10 and an additional nine within day +100. Therefore, TRM within day +100 is 11/48 (23%) and total TRM is 18/48 patients (37%). This figure is comparable to the transplant mortality of concurrent patients with advanced disease receiving UD grafts in our unit after conditioning with TBI (TRM = 8/27, 30%) (P = 0.8). TRM was significantly lower in FAM as compared to UD transplants (18% vs 51%, P = 0.05) when BM was the stem cell source. One reason for this difference could be the significantly greater number of cells grafted from FAM donors (P = 0.00001). The overall actuarial survival of the whole group of 48 patients at 3 years is 45%.
In conclusion, the combination of THIO-CY-ATG allows engraftment of alternative donor hemopoietic stem cells. Results are similar when using unrelated matched donors or partially mismatched family donors, and particularly encouraging when using G-CSF mobilized bone marrow rather than peripheral blood stem cells. CML patients with advanced disease prepared with the CY-TBI regimen have a comparable outcome. GvHD and immune deficiency remain the most significant problems.
